A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1

NCT06867497 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Adenocarcinoma of the Pancreas

Interventions

DRUG: BR2021
DRUG: BR2021-1

Sponsor

Boryung Pharmaceutical Co., Ltd